T Scott Stroup

Summary

Affiliation: University of North Carolina
Country: USA

Publications

  1. ncbi Correlates of family burden under medicaid managed mental health care
    T S Stroup
    Cecil G Sheps Center for Health Services Research at the University of North Carolina at Chapel Hill, 27599 7160, USA
    Adm Policy Ment Health 29:117-28. 2001
  2. ncbi Concealed medicines for people with schizophrenia: a U.S. perspective
    Scott Stroup
    Department of Psychiatry, The University of North Carolina School of Medicine, Chapel Hill 27599-7160, USA
    Schizophr Bull 28:537-42. 2002
  3. ncbi The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development
    T Scott Stroup
    Department of Psychiatry, University of North Carolina School of Medicine, Neurosciences Hospital, Chapel Hill 27599 7160, USA
    Schizophr Bull 29:15-31. 2003
  4. ncbi Heterogeneity of treatment effects in schizophrenia
    T Scott Stroup
    Department of Psychiatry, University of North Carolina at Chapel Hill, 10301 Neuroscience Hospital, Chapel Hill, North Carolina 27599 7160, USA
    Am J Med 120:S26-31. 2007
  5. ncbi Revised PORT recommendations
    T Scott Stroup
    University of North Carolina at Chapel Hill, 10626 Neurosciences Hospital, Campus Box #7160, Chapel Hill, NC 27599-7160, USA
    Schizophr Bull 30:609-11. 2004
  6. ncbi Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic
    T Scott Stroup
    Department of Psychiatry, University of North Carolina at Chapel Hill, CB 7160, Chapel Hill, NC 27599 7160, USA
    Am J Psychiatry 163:611-22. 2006
  7. ncbi Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia
    Stanley N Caroff
    Department of Psychiatry, Veterans Affairs Medical Center and University of Pennsylvania School of Medicine, Philadelphia, USA
    J Clin Psychiatry 72:295-303. 2011
  8. ncbi Effectiveness of switching antipsychotic medications
    Susan M Essock
    Department of Psychiatry, Division of Health Services Research, Mount Sinai School of Medicine, New York, NY 10029 6574, USA
    Am J Psychiatry 163:2090-5. 2006
  9. ncbi Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial
    Richard S E Keefe
    Department of Psychiatry, John Umstead Hospital, Duke University Medical Center, Durham, NC 27710, USA
    Arch Gen Psychiatry 64:633-47. 2007
  10. ncbi Results of phase 3 of the CATIE schizophrenia trial
    T Scott Stroup
    Department of Psychiatry, School of Medicine, University of North Carolina at Chapel Hill, USA
    Schizophr Res 107:1-12. 2009

Detail Information

Publications61

  1. ncbi Correlates of family burden under medicaid managed mental health care
    T S Stroup
    Cecil G Sheps Center for Health Services Research at the University of North Carolina at Chapel Hill, 27599 7160, USA
    Adm Policy Ment Health 29:117-28. 2001
    ..Predictors of increased family burden were (a) more reported client symptoms and disruptive behaviors, (b) status as a parent, and (c) living with the client...
  2. ncbi Concealed medicines for people with schizophrenia: a U.S. perspective
    Scott Stroup
    Department of Psychiatry, The University of North Carolina School of Medicine, Chapel Hill 27599-7160, USA
    Schizophr Bull 28:537-42. 2002
  3. ncbi The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development
    T Scott Stroup
    Department of Psychiatry, University of North Carolina School of Medicine, Neurosciences Hospital, Chapel Hill 27599 7160, USA
    Schizophr Bull 29:15-31. 2003
    ..If the phase 2 study drug is discontinued, subjects may enter phase 3, in which clinicians help subjects select an open-label treatment based on individuals' experiences in phases 1 and 2...
  4. ncbi Heterogeneity of treatment effects in schizophrenia
    T Scott Stroup
    Department of Psychiatry, University of North Carolina at Chapel Hill, 10301 Neuroscience Hospital, Chapel Hill, North Carolina 27599 7160, USA
    Am J Med 120:S26-31. 2007
    ..Collectively, the CATIE results highlight variable response in the treatment of schizophrenia and demonstrate the need for individualized therapy based on variations in drug efficacy and tolerability among patients...
  5. ncbi Revised PORT recommendations
    T Scott Stroup
    University of North Carolina at Chapel Hill, 10626 Neurosciences Hospital, Campus Box #7160, Chapel Hill, NC 27599-7160, USA
    Schizophr Bull 30:609-11. 2004
  6. ncbi Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic
    T Scott Stroup
    Department of Psychiatry, University of North Carolina at Chapel Hill, CB 7160, Chapel Hill, NC 27599 7160, USA
    Am J Psychiatry 163:611-22. 2006
    ..This randomized, double-blind study compared olanzapine, quetiapine, risperidone, and ziprasidone in patients who had just discontinued a different atypical antipsychotic...
  7. ncbi Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia
    Stanley N Caroff
    Department of Psychiatry, Veterans Affairs Medical Center and University of Pennsylvania School of Medicine, Philadelphia, USA
    J Clin Psychiatry 72:295-303. 2011
    ..We compared the response to antipsychotic treatment between patients with and without tardive dyskinesia (TD) and examined the course of TD...
  8. ncbi Effectiveness of switching antipsychotic medications
    Susan M Essock
    Department of Psychiatry, Division of Health Services Research, Mount Sinai School of Medicine, New York, NY 10029 6574, USA
    Am J Psychiatry 163:2090-5. 2006
    ....
  9. ncbi Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial
    Richard S E Keefe
    Department of Psychiatry, John Umstead Hospital, Duke University Medical Center, Durham, NC 27710, USA
    Arch Gen Psychiatry 64:633-47. 2007
    ..The relative effect of the second-generation (atypical) antipsychotic drugs and older agents on neurocognition has not been comprehensively determined...
  10. ncbi Results of phase 3 of the CATIE schizophrenia trial
    T Scott Stroup
    Department of Psychiatry, School of Medicine, University of North Carolina at Chapel Hill, USA
    Schizophr Res 107:1-12. 2009
    ..We describe the characteristics of the patients who selected each treatment option and their outcomes...
  11. ncbi Effectiveness of antipsychotic drugs in patients with chronic schizophrenia
    Jeffrey A Lieberman
    Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York State Psychiatric Institute, New York, NY 10032, USA
    N Engl J Med 353:1209-23. 2005
    ..We compared a first-generation antipsychotic, perphenazine, with several newer drugs in a double-blind study...
  12. ncbi Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia
    Robert A Rosenheck
    University of North Carolina, Chapel Hill, USA
    Am J Psychiatry 163:2080-9. 2006
    ..Second-generation antipsychotics have largely replaced first-generation antipsychotics for the treatment of schizophrenia, but a large-scale cost/effectiveness analysis has not been attempted...
  13. ncbi Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study
    Jonathan M Meyer
    Department of Psychiatry, University of California at San Diego, USA
    Biol Psychiatry 66:1013-22. 2009
    ..Despite the known CV effects of atypical antipsychotics, there is limited prospective data on IM changes during treatment...
  14. ncbi The association between weight change and symptom reduction in the CATIE schizophrenia trial
    Eric Hermes
    Department of Psychiatry, Yale School of Medicine, 300 George Street, Ste 901, New Haven, CT 06511, USA
    Schizophr Res 128:166-70. 2011
    ..Weight gain and changes in metabolic indicators associated with some antipsychotics may be related to symptom improvement and thus an unavoidable correlate of clinical benefit...
  15. ncbi The neuregulin 1 promoter polymorphism rs6994992 is not associated with chronic schizophrenia or neurocognition
    James J Crowley
    Department of Genetics, University of North Carolina at Chapel Hill, North Carolina 27599 7264, USA
    Am J Med Genet B Neuropsychiatr Genet 147:1298-300. 2008
    ..We were unable to replicate previous associations of rs6994992 with schizophrenia and, moreover, did not find significant associations with age of onset, an estimate of pre-morbid IQ, or neurocognition...
  16. ncbi AKT1 and neurocognition in schizophrenia
    Andrea Poyastro Pinheiro
    Department of Psychiatry, University of North Carolina at Chapel Hill, NC, USA
    Aust N Z J Psychiatry 41:169-77. 2007
    ..Therefore, the association of genetic variation in AKT1 with neurocognition was investigated in patients with schizophrenia...
  17. ncbi No association of the serotonin transporter polymorphisms 5-HTTLPR and RS25531 with schizophrenia or neurocognition
    Thomas I Konneker
    Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7264, USA
    Am J Med Genet B Neuropsychiatr Genet 153:1115-7. 2010
    ..67 and negative symptoms P = 0.46). We were unable to identify association of the triallelic 5-HTTLPR with schizophrenia, neurocognition, or core psychotic symptoms even at levels of significance unadjusted for multiple comparisons...
  18. ncbi Substance use and schizophrenia: adverse correlates in the CATIE study sample
    Karin E Kerfoot
    Department of Psychiatry, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06510, USA
    Schizophr Res 132:177-82. 2011
    ....
  19. ncbi The impact of obesity on health care costs among persons with schizophrenia
    Lydia A Chwastiak
    Department of Psychiatry, Yale School of Medicine, New Haven, CT 06519, USA
    Gen Hosp Psychiatry 31:1-7. 2009
    ..Obesity is the second leading cause of preventable death in the United States and is twice as common among individuals with schizophrenia as the general population...
  20. ncbi Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1
    Jonathan M Meyer
    Department of Psychiatry, University of California, San Diego, USA
    Schizophr Res 101:273-86. 2008
    ..Given concerns over antipsychotic metabolic effects, this analysis explored MS status and outcomes in phase 1 of the CATIE Schizophrenia Trial...
  21. ncbi Effects of antipsychotic medication on psychiatric service utilization and cost
    Aileen Rothbard
    Center for MH Policy and Services Research, Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, USA
    J Ment Health Policy Econ 8:83-93. 2005
    ..Given that acquisition costs of atypical antipsychotics are generally higher than typical antipsychotics, uncertainty exists whether the newer atypicals are cost effective alternatives when used in ordinary practice settings...
  22. ncbi Determining when impairment constitutes incapacity for informed consent in schizophrenia research
    Scott Y H Kim
    Department of Psychiatry, Bioethics Program, and Center for Behavioral and Decision Sciences in Medicine, University of Michigan, 300 North Ingalls, Ann Arbor, MI 48109 0429, and Massachusetts General Hospital, Boston, USA
    Br J Psychiatry 191:38-43. 2007
    ..Although people with schizophrenia display impaired abilities for consent, it is not known how much impairment constitutes incapacity...
  23. ncbi A candidate gene study of Tardive dyskinesia in the CATIE schizophrenia trial
    Huei Ting Tsai
    Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    Am J Med Genet B Neuropsychiatr Genet 153:336-40. 2010
    ..No single marker or haplotype association reached statistical significance after adjustment for multiple comparisons. Thus, we found no support for either novel or prior associations from the literature...
  24. ncbi Minimum clinically important difference in the Positive and Negative Syndrome Scale with data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)
    Eric D A Hermes
    Department of Psychiatry, Yale School of Medicine, New Haven, CT 06511, USA
    J Clin Psychiatry 73:526-32. 2012
    ..Establishing the minimum clinically important difference in the Positive and Negative Syndrome Scale (PANSS) is important to the interpretation of the research and clinical work conducted with this scale...
  25. ncbi The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update
    Troy A Moore
    Department of Psychiatry, The University of Texas Health Science Center at San Antonio, USA
    J Clin Psychiatry 68:1751-62. 2007
    ....
  26. ncbi Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians?
    L Citrome
    Department of Psychiatry, New York University School of Medicine, New York, NY, USA
    Int J Clin Pract 60:933-40. 2006
    ..NNT and NNH can help place the wide array of CATIE results into clinical context, and permits quantification of the differences observed between the antipsychotics that were tested...
  27. ncbi Guest editors' introduction: what can large pragmatic clinical trials do for public mental health care?
    Jeffrey A Lieberman
    Department of Psychiatry, University of North Carolina School of Medicine, Neurosciences Hospital, Chapel Hill, NC 27599 7160, USA
    Schizophr Bull 29:1-6. 2003
  28. ncbi Service use and health status of persons with severe mental illness in full-risk and no-risk medicaid programs
    Joseph P Morrissey
    Cecil G Sheps Center for Health Services Research, University of North Carolina at Chapel Hill, 27599 7590, USA
    Psychiatr Serv 53:293-8. 2002
    ....
  29. ncbi Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations
    T Scott Stroup
    Department of Psychiatry, University of North Carolina at Chapel Hill, CB 7160, Chapel Hill, North Carolina 27599 7160, USA
    Nat Rev Drug Discov 5:133-46. 2006
    ..Practical and large, simple trials that evaluate the comparative effectiveness of antipsychotic drugs in real-world settings can help to meet these needs once a drug has reached the market...
  30. ncbi Practical clinical trials for schizophrenia
    Scott Stroup
    Epidemiol Psichiatr Soc 14:132-6. 2005
  31. ncbi Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine
    Jeffrey A Lieberman
    Department of Psychiatry, CB 7160, University of North Carolina School of Medicine, Chapel Hill, NC 27599 7160, USA
    Neuropsychopharmacology 28:995-1003. 2003
    ..Longer duration of untreated psychosis was associated with lower odds of achieving remission...
  32. ncbi Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial
    Scott Stroup
    Department of Psychiatry, University of North Carolina at Chapel Hill, CB 7160, Chapel Hill, NC 27599 7160, USA
    Schizophr Res 80:1-8. 2005
    ....
  33. ncbi Evaluation of "subject advocate" procedures in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia study
    T Scott Stroup
    Department of Psychiatry, University of North Carolina School of Medicine, University of North Carolina at Chapel Hill, CB 7160, Chapel Hill, NC 27599 7160, USA
    Schizophr Bull 32:147-52. 2006
    ..Nonspecific benefits included good public relations and engagement of family members. Improved training regarding the procedures may be needed to achieve specific goals of enhanced patient autonomy and retention in the study...
  34. ncbi Schizophrenia, VI: Treatments
    Jeffrey A Lieberman
    UT Southwestern Medical Center, Department of Psychiatry, Dallas TX 75390-9070, USA
    Am J Psychiatry 160:1748. 2003
  35. ncbi Science and recovery in schizophrenia
    Jeffrey A Lieberman
    Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York, NY, USA
    Psychiatr Serv 59:487-96. 2008
    ..Future clinical and neuroscience research and service development should emphasize measures of recovery as outcomes for people with schizophrenia...
  36. ncbi Paliperidone for treatment of schizophrenia
    Abraham M Nussbaum
    Department of Psychiatry, University of North Carolina Hospitals, Chapel Hill, NC 27599 7160, USA
    Schizophr Bull 34:419-22. 2008
    ..Regarding the critical comparison of oral paliperidone to risperidone, we have no information and are thus unable to determine if paliperidone has any advantages or disadvantages compared to its well-known parent compound...
  37. ncbi NCAM1 and neurocognition in schizophrenia
    Patrick F Sullivan
    Department of Genetics, University of North Carolina, Chapel Hill, North Carolina 27599 7264, USA
    Biol Psychiatry 61:902-10. 2007
    ..Neural cell adhesion molecule 1 (NCAM1, aliases NCAM and CD56) may be a candidate gene for schizophrenia or for neurocognition in schizophrenia as supported by linkage and functional findings...
  38. ncbi Randomized controlled trials for schizophrenia: study designs targeted to distinct goals
    T Scott Stroup
    Department of Psychiatry, University of North Carolina, Chapel Hill, NC 27599 7160, USA
    Schizophr Bull 34:266-74. 2008
    ..The different objectives of trials should be considered in the interpretation of the complete body of randomized evidence on antipsychotic drugs...
  39. ncbi The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update
    Alexander L Miller
    Department of Psychiatry, The University of Texas Health Science Center at San Antonio, MC 7792, 7703 Floyd Curl Drive, San Antonio, TX 78229 3900, USA
    J Clin Psychiatry 65:500-8. 2004
    ..This article reports the recommendations developed in 2002 and 2003 by a group of experts, clinicians, and administrators...
  40. ncbi The subject advocate: protecting the interests of participants with fluctuating decisionmaking capacity
    Scott Stroup
    University of North Carolina School of Medicine, USA
    IRB 25:9-11. 2003
  41. ncbi Ethnic stratification of the association of RGS4 variants with antipsychotic treatment response in schizophrenia
    Daniel B Campbell
    Department of Pharmacology, Vanderbilt University, Nashville, Tennessee 37232, USA
    Biol Psychiatry 63:32-41. 2008
    ..The central role of RGS4 in regulating signaling via Gi/o coupled neurotransmitter receptors led us to hypothesize that there may be RGS4 genotypes predictive of specific disease phenotypes and antipsychotic treatment responses...
  42. ncbi Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study
    Marvin S Swartz
    Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC 27710, USA
    J Nerv Ment Dis 194:164-72. 2006
    ....
  43. ncbi Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment
    Joseph P McEvoy
    Clinical Research Service, John Umstead Hospital, 1003 12th St, Bldg 32, Butner, NC 27705, USA
    Am J Psychiatry 163:600-10. 2006
    ....
  44. ncbi A national study of violent behavior in persons with schizophrenia
    Jeffrey W Swanson
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27710, USA
    Arch Gen Psychiatry 63:490-9. 2006
    ..Violent behavior is uncommon, yet problematic, among schizophrenia patients. The complex effects of clinical, interpersonal, and social-environmental risk factors for violence in this population are poorly understood...
  45. ncbi Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial
    Marvin S Swartz
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Box 3173, Durham, NC 27710, USA
    Schizophr Bull 29:33-43. 2003
    ....
  46. ncbi Baseline neurocognitive deficits in the CATIE schizophrenia trial
    Richard S E Keefe
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27710, USA
    Neuropsychopharmacology 31:2033-46. 2006
    ..Multiple analyses suggested that a broad cognitive deficit characterizes this sample. These deficits are modestly related to negative symptoms and essentially independent of positive symptom severity...
  47. ncbi Substance use and psychosocial functioning in schizophrenia among new enrollees in the NIMH CATIE study
    Marvin S Swartz
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27710, USA
    Psychiatr Serv 57:1110-6. 2006
    ..This study examined the relationship between substance use and psychosocial functioning in schizophrenia...
  48. ncbi Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia
    Jeffrey W Swanson
    Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, 905 West Main Street, Durham, NC 27710, USA
    Br J Psychiatry 193:37-43. 2008
    ..Violence is an uncommon but significant problem associated with schizophrenia...
  49. ncbi Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease
    Lon S Schneider
    Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    N Engl J Med 355:1525-38. 2006
    ..We assessed the effectiveness of atypical antipsychotic drugs in outpatients with Alzheimer's disease...
  50. ncbi What CATIE found: results from the schizophrenia trial
    Marvin S Swartz
    Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC 27710, USA
    Psychiatr Serv 59:500-6. 2008
    ..Patient characteristics and clinical circumstances affected drug effectiveness; these patient factors are important in making treatment choices...
  51. ncbi Assessment of Medicaid managed behavioral health care for persons with serious mental illness
    H Stephen Leff
    Human Services Research Institute, 2336 Massachusetts Avenue, Cambridge, Massachusetts 02140, USA
    Psychiatr Serv 56:1245-53. 2005
    ..This five-site study compared Medicaid managed behavioral health programs and fee-for-service programs on use and quality of services, satisfaction, and symptoms and functioning of adults with serious mental illness...
  52. ncbi The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study
    Marvin S Swartz
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham NC 27710, United States
    Schizophr Res 100:39-52. 2008
    ..This double-blind study compared a second generation (atypical) antipsychotic drugs compared to a representative older agent for patients with schizophrenia who use or avoid illicit substances...
  53. ncbi Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia
    Sandra G Resnick
    New England Mental Illness Research Education and Clinical Center, Yale University School of Medicine, VA Connecticut Health Care System, NEPEC 182, 950 Campbell Ave, West Haven, CT 06516, USA
    J Behav Health Serv Res 35:215-25. 2008
    ..Consistent with other CATIE results, there were no differences in employment or participation in PSR among these five medications, including the FGA perphenazine...
  54. ncbi Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study
    Marvin S Swartz
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, USA
    Am J Psychiatry 164:428-36. 2007
    ..This study examined the relative effects of the second-generation antipsychotic drugs and an older representative agent on psychosocial functioning in patients with chronic schizophrenia...
  55. ncbi Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study
    T Scott Stroup
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC
    Am J Psychiatry 164:415-27. 2007
    ..This randomized, double-blind study compared olanzapine, quetiapine, and risperidone in patients who had just discontinued the older antipsychotic perphenazine...
  56. ncbi Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial
    Del D Miller
    University of Iowa Carver College of Medicine, Psychiatry Research, 2 105 MEB, 500 Newton Rd, Iowa City, IA 52242 1000, USA
    Schizophr Res 80:33-43. 2005
    ..To examine the clinical characteristics of individuals with schizophrenia that develop tardive dyskinesia (TD) associated with antipsychotic treatment...
  57. ncbi Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1
    Jonathan M Meyer
    Department of Psychiatry, University of California, San Diego, VA San Diego Healthcare System, San Diego, CA 92161, United States
    Schizophr Res 103:104-9. 2008
    ..Given concerns over antipsychotic effects on serum TG, this analysis explored changes in nonfasting TG in phase 1 of the CATIE Schizophrenia Trial...
  58. ncbi Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline
    Henry A Nasrallah
    University of Cincinnati, Cincinnati, OH 45267 0559, USA
    Schizophr Res 86:15-22. 2006
    ....
  59. ncbi Schizophrenia, drug therapy, and monitoring
    Daniel W Bradford
    N Engl J Med 350:415-6. 2004
  60. ncbi The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome
    Jonathan M Meyer
    VA San Diego Healthcare System, USA
    Schizophr Res 80:9-18. 2005
    ....
  61. ncbi The schizophrenia drug-treatment paradox: pharmacological treatment based on best possible evidence may be hardest to practise in high-income countries
    Clive E Adams
    Br J Psychiatry 189:391-2. 2006
    ..Because it is years after a drug is first launched that the full effects become known with confidence, the evidence upon which to base practice in low- and middle-income countries may be less biased than that in richer nations...